1. 012 Efficacy and Safety of Ixekizumab in a Randomized, Double-Blinded, Placebo-Controlled, Phase 3b Clinical Trial in Patients with Moderate-to-Severe Genital Psoriasis. (1st February 2018) Authors: Ryan, C.; Menter, A.; Guenther, L.; Blauvelt, A.; Bissonnette, R.; Yang, F.E.; Potts Bleakman, A. Journal: Journal of sexual medicine Issue: Volume 15(2018)Supplement 1 Page Start: S6 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A phase 2a randomized controlled study to evaluate the pharmacokinetic, safety, tolerability and clinical effect of topically applied Umeclidinium in subjects with primary axillary hyperhidrosis. (7th November 2017) Authors: Nasir, A.; Bissonnette, R.; Maari, C.; DuBois, J.; Pene Dumitrescu, T.; Haddad, J.; Yamaguchi, Y.; Dalessandro, M. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 32:Number 1(2018) Page Start: 145 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. (8th July 2013) Authors: Ports, W.C.; Khan, S.; Lan, S.; Lamba, M.; Bolduc, C.; Bissonnette, R.; Papp, K. Journal: British journal of dermatology Issue: Volume 169:Number 1(2013:Jul.) Page Start: 137 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. A Randomized, blinded assessor study to Evaluate the efFIcacy and safety of etanercept 50 mg once weekly plus as Needed topical agent vs. Etanercept 50 mg twice weekly in patients with moderate to severe plaque psoriasis (REFINE). (1st July 2014) Authors: Papp, K.A.; Barber, K.; Bissonnette, R.; Bourcier, M.; Lynde, C.W.; Poulin, Y.; Shelton, J.; Toole, J.; Vieira, A.; Poulin‐Costello, M. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 29:Number 2(2015:Feb.) Page Start: 361 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. A Randomized, blinded assessor study to Evaluate the efFIcacy and safety of etanercept 50 mg once weekly plus as Needed topical agent vs. Etanercept 50 mg twice weekly in patients with moderate to severe plaque psoriasis (REFINE). (1st July 2014) Authors: Papp, K.A.; Barber, K.; Bissonnette, R.; Bourcier, M.; Lynde, C.W.; Poulin, Y.; Shelton, J.; Toole, J.; Vieira, A.; Poulin‐Costello, M. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 29:Number 2(2015:Feb.) Page Start: 361 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Adapalene 0.1%/benzoyl peroxide 2.5% gel reduces the risk of atrophic scar formation in moderate inflammatory acne: a split‐face randomized controlled trial. (7th December 2016) Authors: Dreno, B.; Tan, J.; Rivier, M.; Martel, P.; Bissonnette, R. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 31:Number 4(2017) Page Start: 737 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Apremilast for the treatment of moderate‐to‐severe palmoplantar psoriasis: results from a double‐blind, placebo‐controlled, randomized study. (15th November 2017) Authors: Bissonnette, R.; Haydey, R.; Rosoph, L.A.; Lynde, C.W.; Bukhalo, M.; Fowler, J.F.; Delorme, I.; Gagné‐Henley, A.; Gooderham, M.; Poulin, Y.; Barber, K.; Jenkin, P.; Landells, I.; Pariser, D.M. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 32:Number 3(2018) Page Start: 403 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. ASN002 demonstrates efficacy and improves inflammation in AD. (1st October 2019) Authors: Bissonnette, R.; Maari, C.; Forman, S.; Bhatia, N.; Lee, M.; Fowler, J.; Tyring, S.; Pariser, D.; Sofen, H.; Dhawan, S.; Zook, M.; Zammit, D.J.; Usansky, H.; Denis, L.; Rao, N.; Song, T.; Pavel, A.B.; Guttman‐Yassky, E. Journal: British journal of dermatology Issue: Volume 181:Number 4(2019) Page Start: e102 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. ASN002 证明有疗效并可改善AD 炎症. (1st October 2019) Authors: Bissonnette, R.; Maari, C.; Forman, S.; Bhatia, N.; Lee, M.; Fowler, J.; Tyring, S.; Pariser, D.; Sofen, H.; Dhawan, S.; Zook, M.; Zammit, D.J.; Usansky, H.; Denis, L.; Rao, N.; Song, T.; Pavel, A.B.; Guttman‐Yassky, E. Journal: British journal of dermatology Issue: Volume 181:Number 4(2019) Page Start: e113 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. (1st August 2020) Authors: Simpson, E.L.; Lacour, J.‐P.; Spelman, L.; Galimberti, R.; Eichenfield, L.F.; Bissonnette, R.; King, B.A.; Thyssen, J.P.; Silverberg, J.I.; Bieber, T.; Kabashima, K.; Tsunemi, Y.; Costanzo, A.; Guttman‐Yassky, E.; Beck, L.A.; Janes, J.M.; DeLozier, A.M.; Gamalo, M.; Brinker, D.R.; Cardillo, T. Journal: British journal of dermatology Issue: Volume 183:Number 2(2020) Page Start: 242 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗